Cellino

Cellino is a Cambridge, Massachusetts-based biotechnology company that develops autonomous biomanufacturing technology using artificial intelligence and laser physics to produce personalized stem cell therapies at scale. The organization utilizes its proprietary Nebula platform to automate the generation of high-quality induced pluripotent stem cells, aiming to enable curative tissue and organ replacement treatments for chronic and degenerative diseases. To distribute these therapies at a population level, the company is establishing point-of-care manufacturing facilities, including an initial hospital-based foundry in direct partnership with Massachusetts General Hospital. The enterprise has raised a $16 million seed funding round to scale its regenerative medicine operations and advanced optical bioprocesses, securing financial backing from prominent venture capital firms such as The Engine and Khosla Ventures. Cellino was officially founded in the year 2017 by co-founders Nabiha Saklayen, Marinna Madrid, and Matthias Wagner.

High-Level Overview

Cellino Biotech is a regenerative medicine company developing an AI-guided, autonomous biomanufacturing platform for scalable production of personalized cells, tissues, and organs from patients' own induced pluripotent stem (iPS) cells.[1][2][3][4][5] It serves patients with degenerative diseases like macular degeneration, Parkinson's, diabetes, Alzheimer's, and kidney disease by solving the core problem of inefficient, manual stem cell production, which limits scalability and accessibility of cell therapies.[1][2][4][5] The Nebula™ platform automates differentiation, editing, and expansion using deep learning, laser cell management (NanoLaze), and optical bioprocesses, achieving 10x faster programming of mature cells with high yield (targeting 80%) and no immunosuppression needed.[1][2][3][4] Cellino has raised $96M total funding, including an $80M round, and launched the U.S.'s first Nebula-powered iPSC foundry.[3]

Origin Story

Cellino was founded in 2017 by a complementary team: Marina Saklayen (CEO, background in physics and stem cell biology), Mattias Wagner (CTO, expertise in optics, semiconductors, and instrumentation), blending deep tech with biomedicine.[2] The idea emerged from Saklayen's research on automating cell production variability using machine learning for identification based on FDA-accepted assays, partnering with Wagner to integrate laser delivery for precise gene control via NanoLaze.[1][2] Early traction included $16M seed funding co-led by The Engine and Khosla Ventures (with Humboldt Fund and 8VC), NIH collaborations on retinal cell compatibility studies, and focus on transplantable retinal pigment epithelial cells for vision loss.[1][2][3]

Core Differentiators

• AI-Driven Automation: Deep learning and Cellinoverse simulate biomanufacturing in silico, enabling reproducible, scalable control of iPS cell fate without human variability—10x faster than manual methods.[1][2][4][5]
• Proprietary NanoLaze & Optical Bioprocess: Laser-generated bubbles precisely edit/remove cells and deliver synthetic biology tools for "digital" gene sequencing, producing high-functionality tissues like neurons or kidney cells.[1][2][4]
• Nebula™ Platform: Modular, cassette-based system for distributed foundries or hospital use, standardizing autologous production to accelerate therapies for dozens of diseases.[3][4][5]
• Scalability & Yield: Targets 80%+ yield for personalized, off-the-shelf-like cells; eliminates immunosuppression via patient-sourced therapies, expanding access.[2][3][4][5]

Role in the Broader Tech Landscape

Cellino rides the regenerative medicine revolution, where iPSCs and gene therapies promise cures for degenerative diseases affecting billions (e.g., 196M with macular degeneration, 850M with chronic kidney disease).[2][4][5] Timing aligns with AI/biotech convergence, automating labor-intensive processes to make personalized therapies viable at scale amid aging populations and chronic disease epidemics.[1][2][4] Market forces like FDA recognition of its iPSC tech and biomanufacturing needs favor Cellino, influencing the ecosystem by enabling "biofoundries" for fresh, transplantable cells—pushing beyond one-size-fits-all drugs toward patient-specific replacements.[3][4][6]

Quick Take & Future Outlook

Cellino is poised to dominate autologous biomanufacturing with Nebula foundries scaling "living medicines" for high-prevalence diseases like obesity (890M patients) and diabetes (400M).[3][4][5] Next steps include expanding beyond retinal cells to Parkinson's, muscle disorders, and organs via NIH trials and partnerships, leveraging AI advancements for broader cell types.[2][4] Trends like distributed manufacturing and self-sourced therapies will amplify its impact, potentially transforming regen med from niche to mainstream—delivering Cellino's vision of "your cells, your cure" at population scale.[1][5] This positions it as a high-momentum leader in healing through precision biotech.